Organon & Co.
OGN
Classement en actions
#4359
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Prix de l'action
$13.73
Capitalisation boursière
$3.60B
Changement (1 jour)
-0.26%
Changement (1 an)
47.90%
Pays
US
Échange Organon & Co. (OGN)
Catégorie
Healthcare
EPS pour Organon & Co. (OGN)
EPS au June 2026 TTM : $0.79
Selon les derniers rapports financiers et le cours de l'action de Organon & Co., l’EPS actuel de la société (TTM) est de $0.79. À la fin de 2024, la société avait un EPS de $3.36 une diminution par rapport à celui de 2023, qui était de $4.01.
Historique de l'EPS de Organon & Co. de 2017 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $0.79 | 9.72% |
| 2025 | $0.72 | -78.57% |
| 2024 | $3.36 | -16.21% |
| 2023 | $4.01 | 11.08% |
| 2022 | $3.61 | -32.27% |
| 2021 | $5.33 | -37.44% |
| 2020 | $8.52 | -32.97% |
| 2019 | $12.71 | 49.35% |
| 2018 | $8.51 | 19.69% |
| 2017 | $7.11 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $29.89 | 3,683.54% |
US
|
|
| $6.60 | 735.44% |
US
|
|
| $3.55 | 349.37% |
US
|
|
| $1.26 | 59.49% |
US
|
|
| $20.39 | 2,480.89% |
CH
|
